Aurothioglucose
Risk Factor: CM
Class: Immunologic agents
/ Antirheumatic agents
Contents of this page:
Fetal Risk Summary
Aurothioglucose is a sterile suspension administered by IM injection for the adjunctive treatment of early active rheumatoid arthritis. The manufacturer recommends against its use in pregnancy because of the potential nephrotoxicity of gold superimposed on the normal physiologic renal changes that occur in pregnancy (1).
Gold sodium thiomalate, administered by SC injection, is teratogenic in rats and rabbits (See Gold Sodium Thiomalate). The administration of oral gold to pregnant rabbits from days 6 through 18 of pregnancy, in doses that produced both maternal and embryo toxicity, also resulted in multiple congenital malformations (1). The malformations observed included abdominal wall defects (gastroschisis and umbilical hernia), anomalies of the brain, heart, lung, and skeleton, and microphthalmia.
See Gold Sodium Thiomalate for the clinical use of gold compounds in pregnant humans.
Breast Feeding Summary
See Gold Sodium Thiomalate.
References
-
Product information. Solganal. Schering, 2000.
